Latest News

Research
Tuesday, July 26, 2016
Researchers from the Yale University Department of Dermatology recently conducted a review of all studies that have assessed the health-related quality of life of people with alopecia areata (AA). These results were published last week online in the Journal of the American Academy of Dermatology. Collectively, the studies included data from 1,986 patients and showed that in general people with AA experience a negative impact on quality of life, particularly in terms of social functioning and psychological and emotional distress. The quality of life experienced by people with AA is similar to...Read more
Research
Friday, May 27, 2016
The progress being made right now is thrilling, with advances in alopecia areata research and several treatments in development. The excitement was palpable during the many educational sessions, poster exhibits, social programs, and networking opportunities at the 75 th Annual Society for Investigative Dermatology (SID) conference in Scottsdale, Arizona, which took place May 11 to 14. This new era of research was celebrated by young, up-and-coming investigators, seasoned research advisors and industry representatives during NAAF’s Reception and Research Update. Together, NAAF President and...Read more
Research
Monday, April 4, 2016
NAAF representatives traveled to Washington, D.C., this month to attend the largest dermatology event of the year — the 74 th American Academy of Dermatology (AAD) Annual Meeting, which was packed with outstanding educational sessions, poster exhibits, social programs, and endless networking opportunities. Exhilarating new interest in the field of alopecia areata research was evident throughout this five-day meeting, held March 4 to 9, with over 18,500 attendees from across the United States — and the world! NAAF staffers participated in numerous medical and scientific groups that met in...Read more
Research
Monday, December 21, 2015
More exciting news for an emerging treatment in alopecia areata, and one patients tend to feel more comfortable with: a topical medication applied directly to the affected areas of hair loss. In the alopecia areata (AA) community, we are more or less familiar with the term “JAK inhibitors” as potential therapy for alopecia areata. Because of their role as immune modulators, having them available as topical agents is a very promising concept, and it has already been tested in mouse models. In this month’s online issue of JAMA Dermatology, Dr. Craiglow and colleagues from Yale University,...Read more
Research
Thursday, December 3, 2015
Another treatment shows success in three patients according to an article just published in the Journal of Allergy and Clinical Immunology . Recent developments in alopecia areata research have pointed out the similarities it shares with other autoimmune diseases. This has been of large benefit, allowing researchers to test medications in alopecia areata that are already approved and proven safe in other conditions. One such medication, ustekinumab, was tested by Dr. Emma Guttman-Yassky, and her research team at Mount Sinai hospital, NYC. Their new publication shows how extensive alopecia...Read more
Research
Monday, November 9, 2015
We are thrilled to announce the publication of NAAF’s fifth Alopecia Areata Research Summit, From Targets to Treatments: Bridging Autoimmune Research to Advance Understanding of Alopecia Areata, in the prestigious Journal of Investigative Dermatology Symposium Proceedings (JIDSP). Our semi-annual research summits serve to distill learning, chart the path forward and guide the research grants made through NAAF’s Treatment Development Program. The 2014 meeting represented a pivotal moment for alopecia areata research and treatment development with early stage clinical trials of drugs targeting...Read more
Research
Tuesday, September 22, 2015
This year, NAAF received 13 promising Research Grant proposals requesting over $1.8 million in response to our Research Funding Announcements (RFAs) publicized last May. NAAF’s Research Grant opportunities are designed to support scientists and clinicians to pursue promising research ideas and innovative projects that will advance the development or discovery of safe, effective, affordable treatments and a cure for alopecia areata. Each application will undergo a two-step, patient-centered review process to determine its eligibility for funding. The first phase of peer review is currently...Read more
Research
Wednesday, May 27, 2015
NAAF is pleased to publicize the release of 2015 Research Funding Announcements (RFAs) that outline Research Grant opportunities the support scientists and clinicians at various career stages and in numerous aspects of the field to pursue promising research ideas and innovative projects that will advance the development or discovery of safe, effective, affordable treatments and a cure for alopecia areata. These RFAs were publicized at the Society for Investigative Dermatology (SID) conference in Atlanta, Georgia in early May. This was a fitting venue for announcing RFAs since this meeting...Read more
Research
Friday, April 3, 2015
RXi Pharmaceuticals has entered into a collaboration with Dr. Maria Hordinsky of the University of Minnesota and the National Alopecia Areata Foundation (NAAF) for the study of Samcyprone™ in the treatment of alopecia areata, with the aim to optimize the treatment regimen of diphencyprone is this dermatological disorder, and to better understand the mechanism of action of the drug in this disease. This collaboration could lead to novel targets for development of potent RNAi compounds against this disease based on our sd-rxRNA® platform. Maria K. Hordinsky, M.D. is Professor and Chair of the...Read more
Research
Wednesday, April 1, 2015
On March 22, 2015 a group of seventeen NAAF patient-stakeholders, NAAF staffers Laura Ralph and Maureen Smith, and ten representatives from a biopharmaceutical company convened in New York City, at the request of the biopharma for a focus group to learn more about what patients would want-and not want – in a treatment or cure. The five-hour focus group was filled with personal stories of struggle and triumph, helpful insights about what it means to live with alopecia areata, and important things to consider when developing a treatment such as its safety, efficacy, and durability. All...Read more
Research
Tuesday, March 24, 2015
On March 24, 2015, Genetic Alliance announced the National Alopecia Areata Foundation (NAAF) as one of the fifteen awardees for Phase I of its initiative to create a ‘white label’ of the Platform for Engaging Everyone Responsibly (PEER). PEER enables individuals to share health information with researchers and each other on their own terms to advance an understanding of health and disease, and to accelerate the development of cohorts for clinical trials. The fifteen selected awardees will work with Genetic Alliance to develop and refine the ‘white label’ PEER while engaging their communities...Read more
Research
Tuesday, February 10, 2015
The fifth Alopecia Areata Research Summit, From Targets to Treatments: Bridging Autoimmune Research to Advance Understanding of Alopecia Areata, brought together leading experts with new investigative partners to discuss exciting new discoveries and identify opportunities to further advance alopecia areata research. This meeting, held December 4 to 5 in Bethesda, Maryland, represented a pivotal moment for alopecia areata research and treatment development with early stage clinical trials of drugs targeting auroimmune pathways showing promising hair regrowth for the first time ever. Among the...Read more
Research
Tuesday, February 10, 2015
During the first week of February, President Obama submitted his budget proposal for Fiscal Year 2016 to the newly-installed 114th Congress. It is particularly noteworthy the President’s budget mentions alopecia areata research activities, which indicates that the alopecia areata research portfolio is a priority for the National Institutes of Health (NIH). The President requests $31.31 billion for NIH, a recommended increase of $1 billion over FY 2015, with $533 million of that amount allocated towards NIH's National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS), an...Read more
Research
Wednesday, December 24, 2014
Please note: This article has not been peer-reviewed or vetted by NAAF research advisors. NAAF neither endorses nor discredits the results and claims contained in the article. We pass along this information as it may be of interest to our community. We would appreciate your response if you have any relevant experience.Read more
Research
Monday, June 30, 2014
The National Alopecia Areata Foundation congratulates its advisors, Drs. Raphael Clynes, Angela Christiano and Julian Mackay-Wiggan, and their team at Columbia University Medical Center for their exciting preliminary findings with a drug approved by the FDA for the treatment of myelofibrosis (a type of bone marrow cancer) which has produced near complete hair regrowth in several patients with moderate-to-severe alopecia areata. We applaud the publication of these results in Nature Medicine. This triumph is the result of a long history of Genome Wide Association Studies conducted by Dr...Read more

Pages